Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (954)	7/18/2000 7:14:38 PM
From: Stephen O	Read Replies (2) \| Respond to of 1321

Just being a devil's advocate but it seems as though people are thinking this way as of now. The share price of QLT is predicated on a certain cash flow stream for treatment way into the future. If something comes along in 2 years that affects that well the value of QLT shares drops. So even if Miravant is 2 years away 500,000 people, your number, can be treated with Visudyne by the specialists for the next 2 years but ongoing is not a certainty. And if the specialist is not paid by someone then most won't treat the penniless. Perhaps you can organise a charity to help pay the freight.

To: Ian@SI who wrote (954)	7/18/2000 9:37:42 PM
From: Ian@SI	Read Replies (1) \| Respond to of 1321

A couple more reiterations today. The price target may have been increased. I don't remember the prior targets. Ian. +++++++++++++ Company Tckr Broker Rating Target QLT Photother. QLTI DB Alex. Brown Strong Buy $ 91 QLT Photother. QLTI Lehman Brothers Buy $100